title: Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol.
authors.affiliation: Department of Transplantation, Rabin Medical Center, Beilinson Campus, Petah-Tiqwa, Israel. rutir@clalit.org.il
authors.forename: R
authors.initials: R
authors.lastname: Rahamimov
authors.forename: A
authors.initials: A
authors.lastname: Yussim
authors.forename: T
authors.initials: T
authors.lastname: After
authors.forename: S
authors.initials: S
authors.lastname: Lustig
authors.forename: N
authors.initials: N
authors.lastname: Bar-Nathan
authors.forename: E
authors.initials: E
authors.lastname: Shaharabani
authors.forename: Z
authors.initials: Z
authors.lastname: Shapira
authors.forename: E
authors.initials: E
authors.lastname: Shabthai
authors.forename: E
authors.initials: E
authors.lastname: Mor
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000077552:Basiliximab; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D019520:Living Donors; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D009173:Mycophenolic Acid; D016559:Tacrolimus